Borrelli Eric P, Saad Peter, Barnes Nathan, Lucaci Julia D
Health Economics and Outcomes Research, Medication Management Solutions (MMS), Becton, Dickinson and Company, San Diego, CA.
Medical Affairs, MMS, Becton, Dickinson and Company, Durham, NC.
J Manag Care Spec Pharm. 2025 May;31(5):512-519. doi: 10.18553/jmcp.2025.31.5.512.
The Medicare Star Ratings Program, managed by the Centers for Medicare & Medicaid Services, assesses Medicare health plan performance. This program consists of quality measures that evaluate plan performance for both Medicare Part C and Part D, including 3 key medication adherence measures.
To assess the potential relationship between performance on medication adherence measures and overall star rating performance for Medicare Advantage (MA) health plans.
An analysis was conducted using annual Medicare Star Rating health plan performance data from 2015 to 2024 to assess the impact of performance on medication adherence measures on health plan overall star rating. Numerical percentages were calculated to assess the rates of a health plan achieving at least a 4-star overall rating if they achieved 4 or more stars, as well as a 5-star rating on each medication adherence measure or composite measure.
From 2015 to 2024, 4,213 health plan contracts received a star rating, of which 2,076 achieved at least a 4-star overall rating (49.3%). For plans achieving at least 4 stars on the medication adherence measures, 70%-74% of them also achieved at least a 4-star overall summary rating, depending on the specific measure. Among plans achieving 5 stars on any adherence measure, 85%-90% of them achieved at least a 4-star overall rating.
Assessing a decade of the Medicare Star Rating performance data showed that MA health plans that performed well on the medication adherence measures also had a high rate of achieving a 4-star overall rating. Future research should explore the interplay between medication adherence measures and other Medicare Star Rating criteria.
由医疗保险和医疗补助服务中心管理的医疗保险星级评定计划评估医疗保险健康计划的表现。该计划包括评估医疗保险C部分和D部分计划表现的质量指标,其中包括3项关键的药物依从性指标。
评估医疗保险优势(MA)健康计划在药物依从性指标上的表现与总体星级评定表现之间的潜在关系。
利用2015年至2024年的年度医疗保险星级评定健康计划表现数据进行分析,以评估药物依从性指标表现对健康计划总体星级评定的影响。计算了数字百分比,以评估健康计划在每项药物依从性指标或综合指标上获得4星及以上评级时,获得至少4星总体评级的比例,以及获得5星评级的比例。
2015年至2024年,4213份健康计划合同获得了星级评定,其中2076份(49.3%)获得了至少4星的总体评级。对于在药物依从性指标上获得至少4星的计划,根据具体指标,其中70%-74%的计划也获得了至少4星的总体综合评级。在任何一项依从性指标上获得5星的计划中,85%-90%的计划获得了至少4星的总体评级。
对十年医疗保险星级评定表现数据的评估表明,在药物依从性指标上表现良好的MA健康计划获得4星总体评级的比例也很高。未来的研究应探讨药物依从性指标与其他医疗保险星级评定标准之间的相互作用。